Powering the Age of Immune Medicine

JPM 2021 Healthcare Conference
Safe Harbor

This presentation has been prepared by Adaptive Biotechnologies Corporation ("we," "us," "our," "Adaptive" or the "Company") and is made for informational purposes only. The information set forth herein does not purport to be complete or to contain all relevant information. Statements contained herein are made as of the date of this presentation unless stated otherwise. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

This presentation contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are intended to be covered by the "safe harbor" created by those sections. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our development plans, our preclinical and clinical results and other future conditions. In some cases, you can identify forward-looking statements by the following words: "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. All statements, other than statements of historical facts, contained in this presentation are forward looking statements, including statements regarding the ability to map adaptive immune responses to COVID-19, Lyme disease or other infectious diseases, the ability to leverage any such findings to advance solutions to diagnose, treat and prevent infectious diseases; regarding our future financial or business performance, conditions, plans, prospects, trends or strategies and other financial and business matters; our current and prospective products and product candidates, including clonoSEQ, immunoSEQ T-MAP COVID and T-Detect products, discovery and development of neutralizing antibodies and their expected efficacy with respect to SARS-CoV-2 and other disease states, planned non-IDE clinical studies, clinical trials and preclinical activities, research and development costs, current and prospective collaborations; the estimated size of the market for our products and product candidates; the timing and success of our development and commercialization of our anticipated product candidates; the availability of alternative therapies for our target markets; and the other risks and uncertainties described in our filings with the Securities and Exchange Commission including the Risk Factors and Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Quarterly Reports on Form 10-Q and our Annual Report on Form 10-K, including our most recent Quarterly Report on Form 10-Q filed on November 10, 2020. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. Risks and uncertainties could cause actual results to differ materially from those expressed in our forward-looking statements. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein.

Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the Company's own internal estimates and research. While the Company believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while we believe our own internal research is reliable, such research has not been verified by any independent source.
Using the immune system as the source-code for immune medicine

IMMUNE SYSTEM

T Cells

B Cells

IMMUNE MEDICINE

GENETICS

DATA

Research, Diagnostics, Drug Discovery
We translate the genetics of the immune system into clinical products

"One" Immune Medicine Platform

Synergistic Data Interplay

Immune Medicine Products

Immunoseq® is available as a FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect minimal residual disease (MRD) in bone marrow samples from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). clonoSEQ is also available for use in other lymphoid cancers as a CLIA-validated laboratory developed test (LDT) service. For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit clonoSEQ.com/technical summary.

T-Detect™ is an IVD for prescription use only. This test has not been cleared or approved by the FDA. The T-Detect COVID Assay is available for use as a CLIA-validated laboratory developed test (LDT). immunoSEQ® and immunoSEQ® T-MAP™ COVID are for Research Use Only. Not for use in diagnostic procedures.
Immune receptor data leads to products across multiple business areas

**COVID-19**

- **T-Detect**: 1st launched indication confirms recent or prior infection

### Clinical Diagnostics
- **T-Cell B-Cell COVID Data**

### Drug Discovery
- **Neutralizing antibodies**
  - Identify potent antibodies against SAR-CoV-2

### Life Science Research
- **immunoSEQ T-MAP COVID**
  - Annotate immunoSEQ samples to specific SAR-CoV-2 antigens

---

**AstraZeneca**

**UNIVERSITY OF OXFORD**

**BILL & MELINDA GATES FOUNDATION**

**Adaptive biotechnologies**
Immune receptor data leads to products across multiple business areas

CANCER

Cancer: early and accurate detection, MRD monitoring

- Clinical Diagnostics
- Cancer TCRs
- Drug Discovery
- Life Science Research

ImmunoSEQ T-MAP Cancer
Mapping TCRs to cancer antigens for drug development

AstraZeneca

Cell Therapy Cancer
Identifying optimal clinical TCR candidates (shared; personalized)

Genentech
A Member of the Roche Group

Adaptive biotechnologies
Uniquely positioned as an immune medicine product development engine

Moats Around our Platform

- Clinically validated technology and applications with strong IP
- Computational biology & machine learning
- Clinical Immunomics database

Broad Applications with >$54B TAM

- Speed
- Scale
- Precision

1 Includes: ~$1B in life science research for pharma and academic; ~$22.3B in clinical diagnostics (~$4.5B MRD monitoring and ~$22.3B in accurate and early detection); ~$31.4B in drug discovery (only includes GNE collaboration agreement for cell therapy in oncology)
Multiple opportunities for growth

Academic (RUO)
Pharma (RUO)

Life Sciences Research

Diagnostics: clonoSEQ

Genentech
Oncology
Auto-immune
COVID-19
Make
Monitor

Drug Discovery

Cell Therapy
Neutralizing Antibodies
Target Discovery
Vaccines

Diagnostics: clonoSEQ

Tumor Type 2
Autoimmune Monitor
Make Predictive Dx

Adaptive biotechnologies

T-Detect

FDA-cleared
Available as LDT
Pipeline Diagnostics
Pipeline Cell Therapy
Pipeline Neutralizing Antibodies

ALL*
MM*
CLL*
NHL**

COVID-19**
Lyme†
GI Diseases†
Ovarian†
Tumor Type 1
Tumor Type 2
Life Science Research
immunoSEQ
immunoSEQ, quantifying immunology

**Repertoire Properties**

- Pioneer of immunosequencing
- Used by >2,400¹ researchers; by >165¹ biopharma partners; in >600² trials; 700 publications
- Increasing RUO Kit adoption for long term growth
  - Signed ~25 new Core Lab partnerships; CRO (Q2)

**T-Cell Fraction**

**Public Clones**

**Mapping**

---

**immunoSEQ**

- Mapping T-cell immune responses to specific antigens
- immunoSEQ T-MAP COVID: 1st application to measure T-cell response to SARS-CoV-2 vaccines
  - Pharma partners (AZ, Oxford/BMGF)
- immunoSEQ T-MAP Cancer: 1st pan portfolio deal (AZ) to map the immune response to cancer antigens

---

¹ Statistics as of July 2020.
² Statistics as of November 2019.
clonoSEQ, MRD monitoring gold standard in blood cancer

Counts remaining patient specific cancerous cells after treatment

**MRD Clinical Testing**
- FDA cleared in MM, ALL (bone marrow) and CLL (bone marrow, blood)
- Reimbursed by CMS and national plans covering ~225 million lives
- Utilized in all 30 NCCN centers, >180 institutions, for >14k unique patients

**MRD Pharma Trials**
- Test of choice >40 biopharma companies in >190 clinical trials
- FDA drug approvals demonstrate utility of MRD
  - Venetoclax, Blinatumomab, Daratumumab
- >$300M in potential future milestones
Unprecedented number of clonoSEQ abstracts at ASH 2020

- **46** ABSTRACTS ACCEPTED
- **18** ORAL PRESENTATIONS
- **26** PHARMA PRESENTATIONS
- **28** POSTER PRESENTATIONS
- **3** RWE PRESENTATIONS

Data Highlights the Real-World Benefits

- **Better Outcomes**
  - Improved PFS following decision to change therapy based on MRD \( [P=0.006] \)

- **Less Invasive Testing**
  - Strong correlation of PB and BM MRD in ALL \( [r=0.87; \ p<0.0001] \)

- **Reduced Cost of Care**
  - MRD-informed discontinuation of maintenance in MM \( [$181M annual savings] \)
clonoSEQ lifecycle plan focused on increasing access for patients

1. Moving Into Blood
   - MM: trial ongoing; data expected in 2021
   - NHL: ongoing ISTs and pharma trials

2. Increasing Awareness
   - Direct-to-patient campaign
   - Watch Registry; our U.S prospective study

3. Expanding Team & Coverage
   - U.S: adding hematology specialist team
   - Ex-US: increasing tech transfer presence

*This use is not cleared or approved by the FDA and is available as part of Adaptive's CLIA-validated LDT service
Clinical Diagnostics
T-Detect
T-Detect, a new category of immune-based diagnostics

Relevance of T-cells

- T-cells play a central role in the immune response to any disease, but have been difficult to study due to massive diversity
- Our TCR-antigen map makes it possible to leverage the natural diagnostic power of T-cells
  - Sensitive, specific, naturally amplified, systemic, persistent

T-Detect Indications

- T-Detect COVID: 1st indication to confirm SARS-CoV-2 recent or past infection (available as LDT)
- T-Detect Lyme: 2nd indication under development
- 3rd T-Detect signal for Crohn's disease confirmed
- Multiple diseases in the pipeline
First indication, T-Detect COVID

1st T-Cell Based Test to Confirm Past COVID Infection

Help patients get the answers they need. Serology tests may miss patients who had COVID-19; T-cells have the answer.

T-Cells: Evolved to Detect

Your employees want to know if they had COVID. T cells have the answer.

Go-to-Market Strategy

- Targeting self-pay consumers; concierge medicine; employers; public health agencies
- Available at T-Detect.com
  - Implementing “virtual HCP” capabilities
  - Opt-in for ongoing research about immunity
- Submitted for EUA clearance in Dec 2020
- Longer term reimbursement strategy contemplates vision of a pan disease product offering
Accelerating disease mapping through R&D pipeline

T-Detect Pipeline

- T-Detect COVID infrastructure enables acceleration of future indications
- Actively evaluating dozens of indications simultaneously to put into our 5 stage R&D funnel
- Moving diseases at a faster rate through the funnel

I Prioritize Diseases
II Prepare for Modeling
III Identify Initial Signal
IV Develop Clinical Algo
V Finalize Algo for Dev

- 5 indications
- 4 indications
- Ovarian Cancer
- Crohn’s Disease
- SARS-CoV-2
- Lyme Disease

T-Detect Vision

1 Improve SOC Dx
2 Differential Diagnosis
3 Population Immunomics
- Disease by disease
- Panel of disease
- Any mapped disease

1 Development completed and available for use as a CLIA-validated laboratory developed test (LDT)
Drug Discovery
Drug discovery, identifying best-in-class TCR and BCR candidates

**TruTCR**
- Partner with GNE to characterize TCRs against cancer antigens for cellular therapy
  - Shared and private products under development
  - Ability to pursue partnerships outside of oncology

**TruAB**
- Identified potent neutralizing antibodies against several parts of SARS-CoV-2, including outside of RBD
  - Top Abs with strong live virus neutralization
  - Low concentrations, single digit pM IC 50 live virus
Focus on 2nd shared product and scaling private product development

2021

1st Shared Product

IND submission

TCR selection for 2nd Shared Product

2022

2nd Shared Product

Complete TruTCR data package

1st Shared Product

Speed to the clinic

Private Product

Personalized Approach
Patient-specific TCRs

Private Product

Prototype

Path to IND
Potent neutralizing antibodies against COVID delivered from our platform

Current environment

- SARS-CoV-2 is likely endemic in our population
- Virus mutates
- Current antibody therapies are effective but limited:
  1. Timing and method of administration
  2. Cost
  3. Unclear efficacy against new variants of the virus

Need for improved antibody therapies

Our antibodies can solve the current issues

- Search at scale identifies more potent antibodies against multiple parts of the virus, resulting in:
  - Potential use at low concentration that may enable simpler administration at lower cost
  - Potential to avoid mutations

<table>
<thead>
<tr>
<th>NAb clone</th>
<th>Spike Region</th>
<th>Binding EC_{50} (pM)</th>
<th>Live Virus Neutralization Average IC_{50} (pM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADPT02050</td>
<td>RBD</td>
<td>25</td>
<td>3 (0.5 - 16)</td>
</tr>
<tr>
<td>ADPT00980</td>
<td>RBD</td>
<td>23</td>
<td>8 (5 - 13)</td>
</tr>
<tr>
<td>ADPT02020</td>
<td>RBD</td>
<td>88</td>
<td>9 (5 - 23)</td>
</tr>
<tr>
<td>ADPT02793</td>
<td>S1 (non-RBD)</td>
<td>Pending</td>
<td>11 (0 - 30)</td>
</tr>
<tr>
<td>ADPT02019</td>
<td>Trimer (non-RBD)</td>
<td>24</td>
<td>33 (19 - 56)</td>
</tr>
<tr>
<td>Control</td>
<td>RBD</td>
<td>150 ± 30</td>
<td>827 (480 - 1380)</td>
</tr>
</tbody>
</table>

IC_{50}s are averages estimated from replicates and up to 3 different experiments. Range shows estimated 95% confidence interval.
2021 Catalysts

**Life Science Research**
- Embed T-MAP COVID into SARS-CoV-2 vaccine trials
- Expand immunoSEQ T-MAP data offering into other disease categories
- Expand distribution of immunoSEQ RUO kit

**Clinical Diagnostics**
- FDA clearance for clonoSEQ ALL in blood
- T-Detect COVID EUA clearance; commercialization
- ImmuneSENSE study completion and T-Detect Lyme launch
- Confirm additional T-Detect signal(s)

**Drug Discovery**
- GNE expected to file IND for first shared product in Q1 2021
- Private product proof of concept data expected Q1 2021
- Complete 2nd share product data package for GNE
- Pursue neutralizing antibody pathway
If you believe in Immune Medicine, believe in Adaptive

- Differentiated vision
- Unparalleled science & data
- Strong execution record
- Diverse & experienced team
- Well capitalized
Thank You.
### Appendix: Clinical portfolio and pipeline

<table>
<thead>
<tr>
<th>Diagnostic Product Plan</th>
<th>Signal Discovery</th>
<th>Clinical Validation</th>
<th>FDA Submission</th>
<th>FDA Clearance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monitor MRD: clonoSEQ&lt;sup&gt;*&lt;/sup&gt;</td>
<td>Multiple Myeloma</td>
<td></td>
<td></td>
<td>✔️</td>
</tr>
<tr>
<td></td>
<td>Acute Lymphoblastic Leukemia</td>
<td></td>
<td></td>
<td>✔️</td>
</tr>
<tr>
<td></td>
<td>Chronic Lymphocytic Leukemia</td>
<td></td>
<td></td>
<td>✔️</td>
</tr>
<tr>
<td></td>
<td>Non-Hodgkin’s Lymphoma (Subtypes)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Accurate Detection: T-Detect&lt;sup&gt;®&lt;/sup&gt;</th>
<th>COVID-19</th>
<th>Lyme Disease</th>
<th>GI Diseases (Celiac, Crohn’s)</th>
<th>Ovarian cancer</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Drug Discovery Product Plan</th>
<th>Early Development</th>
<th>IND Submission</th>
<th>Clinical Development</th>
</tr>
</thead>
<tbody>
<tr>
<td>TCR-Based Cell Therapies*</td>
<td>1&lt;sup&gt;st&lt;/sup&gt; Shared</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2&lt;sup&gt;nd&lt;/sup&gt; Shared</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Personalized</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| Neutralizing Antibodies**   | COVID-19         |

---

* Product candidates in development as part of our worldwide collaboration and license agreement with Genentech. The “1st Shared” and “2nd Shared” product candidates refer to the two lead clinical product candidates selected from our library of TCRs that target cancer antigens present in many cancer patients. Genentech will determine the timing of discussions with, and submissions to the FDA.

** Product candidates in development.